000 03479nam a22004935i 4500
001 978-1-4614-7654-2
003 DE-He213
005 20140220082830.0
007 cr nn 008mamaa
008 130804s2013 xxu| s |||| 0|eng d
020 _a9781461476542
_9978-1-4614-7654-2
024 7 _a10.1007/978-1-4614-7654-2
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aBonavida, Benjamin.
_eeditor.
245 1 0 _aResistance to Immunotherapeutic Antibodies in Cancer
_h[electronic resource] :
_bStrategies to Overcome Resistance /
_cedited by Benjamin Bonavida.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2013.
300 _aXIII, 202 p. 29 illus., 15 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v2
505 0 _aPreface -- Introduction and generation of chimeric and humanized mAbs -- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment -- Antibodies directed against different major cancers: Effects when used  alone or in combination with drugs -- Mechanisms of antibodies-mediated responses, in vitro and in vivo -- Molecular Pathways -- Molecular Signatures -- Identification of resistance targets for intervention -- Various chemicals that can sensitize resistant tumor cells -- Other mAbs -- Proteasome inhibitors -- Divalent mAbs -- Antibodies coupled to chemical inhibitors -- Antibodies coupled to cytokines -- Nanoparticles with mAbs -- Index.
520 _aThe current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aImmunology.
650 0 _aMonoclonal antibodies.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aMolecular Medicine.
650 2 4 _aImmunology.
650 2 4 _aAntibodies.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781461476535
830 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v2
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-7654-2
912 _aZDB-2-SBL
999 _c95957
_d95957